Chengdu Maikang Biological Technology Co., Ltd. updated its listing application review status on the Shanghai Stock Exchange on May 27, and its IPO application has been accepted.
According to Wall Street Finance, the company is a biopharmaceutical enterprise dedicated to the research, production, and commercialization of innovative vaccines and novel adjuvants. Maikang Bio is a market leader in the field of novel vaccine adjuvant research and development in China. Novel vaccine adjuvants are the &#34;chips&#34; of innovative vaccine development, helping to promote the research and development of more innovative vaccines and providing more response options in the face of major public health events. Novel vaccine adjuvants have strategic significance, including supply chain security.
The company plans to publicly issue no less than 12.9 million shares of ordinary shares in RMB. The funds raised from this public offering, after deducting issuance costs, will be used entirely for projects related to the company's main business, specifically as follows: core vaccine research and development projects, innovative prevention and treatment vaccine research and development projects, industrialization base construction projects, and marketing and service network construction projects.
In 2025, the company's top five customers will be Wuhan Keqian Biological Co., Ltd., Dalian Lejia Technology Co., Ltd., Reap Bio Co., Ltd., Shandong Haili Biological Products Co., Ltd., and Twin Food (Group) Co., Ltd.
In 2025, the company's top five suppliers will be Sichuan Provincial Center for Disease Control and Prevention, Shanghai Chengtai Pharmaceutical Technology Co., Ltd., Henan Provincial Center for Disease Control and Prevention, Beijing Simu Ruike Pharmaceutical Technology Co., Ltd., and Shangqiu City Liangyuan District Center for Disease Control and Prevention.
The company's main competitors include GSK, CanSino, Green Bamboo Bio, and Olin Bio.
Regarding industry development, the global innovative vaccine market continues to grow steadily, with new technology platforms becoming the core driving force. Relevant data shows that the total scale of the global vaccine market will reach USD 66 billion in 2024, with the proportion of innovative vaccines continuously increasing. Cutting-edge technology routes such as mRNA, recombinant proteins, and viral vectors are rapidly maturing, accelerating the landing of new categories such as therapeutic vaccines for tumors and broad-spectrum infectious disease vaccines, becoming key forces driving market growth. The global novel adjuvant market continues to expand, with strong demand for high-end products. Relevant data shows that the global vaccine adjuvant market size will be USD 2.38 billion in 2025, and is expected to increase to USD 3.39 billion by 2031, with a compound annual growth rate of 6.07% from 2026 to 2031. Novel adjuvants can significantly enhance the immunogenicity of vaccines and extend the duration of immune protection, with an increasing application ratio in new vaccines such as mRNA vaccines and recombinant protein vaccines

Maikang's IPO application has been accepted by the Shanghai Stock Exchange: focusing on the research, development, and sales of innovative vaccines and new adjuvants

同壁财经

Keqian Biology

RINGPU

HILE

GlaxoSmithKline plc

CANSINOBIO

CanSinoBIO

LUZHU BIOTECH-B

Olymvax Biopharmaceuticals

GSK plc Sponsored ADR

Maikang's IPO application has been accepted by the Shanghai Stock Exchange: focusing on the research, development, and sales of innovative vaccines and new adjuvants